Lilly and Boehringer eye FDA nod for diabetes combo; White House halts infectious disease studies;

@FierceBiotech: Great panel with $BLUE, $PFE, $AGIO, $GSK and $SNY on the revolution in drug R&D. Video will be up on site tomorrow. | Follow @FierceBiotech

@JohnCFierce: Top 10 Phase III disasters of 2014. Feature | Follow @JohnCFierce

@DamianFierce: RT @DatamonitorMark: David Shlaes: "AZ has told its antibiotics researchers they should make efforts to find other jobs in near future." Blog post via Antibiotics - The Perfect Storm | Follow @DamianFierce

@EmilyMFierce: Human intestinal organoids grown in mice could help personalize treatments. FierceBiotech Research story | Follow @EmilyMFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim are nearing another approval in their long-standing diabetes alliance, as the FDA has accepted their application for a fixed-dose combination of empagliflozin and metformin. Empagliflozin, an SGLT-2 inhibitor, won FDA approval in August and is marketed as Jardiance. News

> The White House has halted funding for so-called gain-of-function studies of infectious diseases like MRSA and SARS, weighing whether such research, in which scientists make viruses more dangerous, are too risky. Story

> The FDA signed off on RegeneRx's plans to resume a Phase III study on RGN-259, an eye drop for the orphan corneal disease neurotrophic keratopathy. More

Medical Device News

@FierceMedDev: 2014's most memorable medtech patent battles. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Nanodevices could be unleashed by DNA-brick self-assembly. Article | Follow @VarunSaxena2

@EmilyWFierce: RIP Shabbvie. Bloomberg piece | Follow @EmilyWFierce

> Illumina up 10% on strongest growth since 2011, raises 2014 guidance. Story

> Google, KKR, Kleiner Perkins invest $542M in virtual reality eyeglass startup. Article

> FDA clears app to monitor brain health on the battlefield. More

> Q&A: CMO says Covidien wants to engage parallel review process. Editor's Corner

Pharma News

@FiercePharma: Actavis, Sanofi, Boehringer jockey bids for OTC specialist Omega Pharma. Report | Follow @FiercePharma

@EricPFierce: Top-read special report Monday: The top 10 most expensive drugs of 2013. Feature | Follow @EricPFierce

@CarlyHFierce: Novartis recruits Nick Cannon for double-whammy flu campaign. FiercePharmaMarketing story | Follow @CarlyHFierce

> AbbVie faces stumbling blocks after cutting cord on $55B Shire deal. Article

> Top investor bails on Valeant bid, backing Allergan-Shire combo instead. Report

> It's back to basics in M&A, and that's a good thing, Actelion CEO says. More

Biotech Research News

> GlaxoSmithKline drug flips off cancer mechanism in aggressive leukemia. Story

> Protein boost restores hearing in deaf mice. More

> Human intestinal organoids grown in mice could help personalize treatments. Story

> Researchers pinpoint potent anti-obesity compounds. More

> Protein switch could boost recovery after heart attack. Article

Pharma Manufacturing News

> Janssen recalls 13,500 bottles of Xarelto because of contamination. News

> Canada cuts Apotex a break on some banned drugs. Report

> BARDA calls on Novartis, GSK, Emergent to pitch in with Ebola drug. Article

> FDA will start the new year with its Office of Quality in place. Item

> Lilly closing 1 Puerto Rico plant next year but investing in another. More

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.